Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
ASCO: BMS' bispecific ADC puts TROP2 drugs on notice
BMS' CMO Cristian Massacesi is already thinking about potential combinations of the EGFRxHER3 bispecific ADC with its BioNTech-partnered pumitamig.
Angus Liu
Jun 2, 2026 8:00am
ASCO: RevMed confident in RAS leadership as rivals square up
May 31, 2026 8:00am
ASCO: Tubulis touts ovarian cancer data that attracted Gilead
May 30, 2026 9:36am
Gilead scraps lead arthritis drug from $405M MiroBio buyout
May 29, 2026 7:18am
After buyout, Gilead is laying off Arcellx staff on both coasts
May 5, 2026 3:12pm
Gilead loosens ties to Arcus as TIGIT dream ends in ph. 3 fail
Apr 21, 2026 3:07am
